GlaxoSmithKline PLC has received orders for a further 96 million doses of vaccine for H1N1 swine flu bringing the number of H1N1 vaccines ordered so far to 291 million. It intends to donate 50 million doses to the World Health Organization from its Canadian manufacturing site where it will dedicate 20 percent of production to providing developing countries with the vaccine. Sanofi Aventis, Novartis AG and CSL Ltd. are also producing vaccines for the US market and have said that currently, a 30 percent yield of the active ingredient from the seasonal viruses that they are using is being achieved. In anticipation of increased demand this fall Novartis AG has shipped doses of the seasonal influenza vaccine to the United States
저작권자 © 메디칼업저버 무단전재 및 재배포 금지